Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABVC, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Radix Polygalae Extract PDC-1421 | Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 · NCT05202327 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABVC holds $122,436 in cash and short-term investments (as of Jun 30, 2026) and burns about $569,328/quarter from operations, an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 87 · High
All of these factors raise substantial doubt about the ability of the Company to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABVC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Eugene Jiang | 5%+ holder (13D) | 131,159 | 0.49% | 2025-07-10 |
Share count 26,654,365 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABVC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →